Lead Product(s) : RKD001
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : DEEPCORE
Deal Size : $1.7 million
Deal Type : Series A Financing
RevolKa Closes $1.7M Series A Extension To Advance Drug Discovery
Details : The proceeds will accelerate RevolKa’s drug discovery and development activities, including RKD001, a protein in discovery for rare diseases.
Product Name : RKD001
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
August 29, 2024
Lead Product(s) : RKD001
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : DEEPCORE
Deal Size : $1.7 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Collaboration
Details : LUCA Science will use its proprietary platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effect...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : Carmine Therapeutics
Deal Size : $900.0 million
Deal Type : Collaboration
Takeda Partners up with Carmine Therapeutics to Develop and Market Rare Disease Candidates
Details : The collaboration will leverage Carmine’s REGENT technology, which is based on red blood cell extracellular vesicles, allowing for repeat dosing, enhanced bio-distribution and larger transgene payload capacity compared to adeno-associated virus-based g...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 30, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : Carmine Therapeutics
Deal Size : $900.0 million
Deal Type : Collaboration